Pfizer Inc. has partnered with Blackstone Inc. to secure up to $1.5 billion in funding for an experimental monthly weight-loss injection. The agreement allows Blackstone to cover development costs through 2028 in exchange for milestone and regulatory approval payments, while Pfizer retains full ownership of the medicine.

Pharmaceutical major Pfizer Inc. has entered into a funding agreement with Blackstone Inc. to secure up to $1.5 billion to support the development of an experimental obesity drug. Announced on Wednesday, the partnership provides Pfizer with additional financial backing as it works to enter the competitive weight-loss treatment market.

Under the terms of the agreement, funds managed by Blackstone Life Sciences will finance up to $1.5 billion in development costs through the year 2028. The funding is specifically designated for an obesity treatment that Pfizer is currently evaluating as a monthly weight-loss injection.

In return for its financial backing, Blackstone will be eligible to receive payments tied to specific sales milestones and US regulatory approval. Despite the funding arrangement, Pfizer will maintain full ownership and control of the medicine.

Pfizer is actively working to establish a presence in the growing weight-loss sector, where it faces established market leaders such as Eli Lilly & Co. and Novo Nordisk A/S. The company's expansion efforts follow its acquisition of Metsera Inc. for up to $10 billion last year. Additionally, Pfizer has outlined plans to advance more than 20 clinical trials within its obesity portfolio this year, a figure that includes 10 late-stage studies.

Cecile Guegan, Chief Financial Officer at Pfizer, noted in a company statement that the agreement will assist the pharmaceutical firm in pursuing its extensive obesity program while simultaneously allowing it to preserve resources for other therapeutic areas.

Blackstone has maintained an active role in funding pharmaceutical development in recent years. Among its previous transactions, the firm reached an agreement in 2024 to help finance clinical trials for Moderna Inc.’s influenza shot, which subsequently received US approval this summer.

"This funding arrangement demonstrates a strategic approach to capital allocation in the capital-intensive pharmaceutical sector. By partnering with private equity through Blackstone Life Sciences to fund high-cost clinical trials, Pfizer is able to mitigate financial exposure in a competitive therapeutic market while retaining full ownership of its intellectual property. For large enterprises and high-growth ventures alike, sharing development risk without diluting asset control is a practical model to finance ambitious pipelines and accelerate time to market." — Dr. Shishir Gupta, Founder & CEO, StartupLanes

Recent StartupLanes Articles

Browse through our 30 latest publications on venture capital, startups, and angel investing.

Indian Markets Open Flat as Investors Await October CPI Inflation Data Nov 14, 2026
Market Watch: Bajaj Finance Launches QIP, Tata Power Announces Leadership Transition, and Alivus Life Acquires Majority Stake in IQGen-X Pharma Nov 14, 2026
Adani Group Partners with Chile's Codelco to Finance Kaburkaala Copper Project Nov 14, 2026
India Streamlines Visa Framework, Cuts Main Categories and Application Fields Nov 14, 2026
Nvidia Board Prepares to Discuss CEO Jensen Huang's Future Following Reports of Personal Conduct Nov 14, 2026
Agri and Food Startup Nutrifresh Outlines 150-Acre Expansion Plan Across South India Nov 14, 2026
Tata Power Appoints Sanjay Banga as CEO-Designate and Approves ₹11,871-Crore Pumped Storage Project Nov 14, 2026
US FDA Flags Rare Vision-Loss Risk for GLP-1 Drugs, Indian Doctors Advise Caution Without Panic Nov 14, 2026
Data Patterns Reports Weak Q2 Performance Amid Uneven Defence Programme Execution Nov 14, 2026
Vardhman Textiles Reports Strong Q2FY27 Performance with 92% Jump in PAT Nov 14, 2026
Tata Power Reports Q2 FY27 Results and Outlines Legal Position on Kleros Dispute Nov 14, 2026
Union Cabinet Approves Extension of Credit Guarantee Funds for Mudra and Stand-Up India Schemes Nov 14, 2026
West Bengal Government Announces New Allowances and Welfare Measures for IAS Officers Nov 14, 2026
Finance Ministry Mandates Electric Vehicles as Default Choice for Central Government Staff Cars Nov 14, 2026
Electric Three-Wheelers Capture 62.6% of Retail Sales in October 2026: FADA Data Nov 14, 2026